<DOC>
	<DOCNO>NCT00240474</DOCNO>
	<brief_summary>The primary objective study test non-inferiority telmisartan 80 mg + hydrochlorothiazide ( HCTZ ) 12.5 mg comparison amlodipine 10 mg + HCTZ 12.5 mg reduce ambulatory systolic blood pressure ( SBP ) last 6 hour 24-hour dose interval ( determined ambulatory blood pressure monitoring : ABPM ) elderly patient predominantly systolic hypertension .</brief_summary>
	<brief_title>A Comparison Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide Control Blood Pressure Older Patients With Predominantly Systolic Hypertension ( ATHOS Study )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Telmisartan , hydrochlorothiazide drug combination</mesh_term>
	<criteria>Inclusion criterion : age least 60 year old mean SBP great 140 mmHg mean DBP le equal 95 mmHg 24hour mean ambulatory SBP great 125 mmHg hypertensive patient current antihypertensive therapy able stop current treatment period eighteen week willing able provide write informed consent Exclusion criterion : woman childbearing potential NOT practice acceptable mean birth control know suspected secondary hypertension mean SBP equal great 200 mmHg hepatic and/or renal dysfunction define follow laboratory parameter : bilateral renal artery stenosis , renal artery stenosis solitary kidney , patient postrenal transplant one function kidney clinically relevant hypokalemia hyperkalemia uncorrected volume sodium depletion primary aldosteronism hereditary fructose intolerance biliary obstructive disorder patient previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensinII receptor antagonist history drug alcohol dependency within previous six month chronic administration medication know affect blood pressure , trial medication concurrent participation another clinical trial investigational therapy within thirty day prior sign consent form . symptomatic congestive heart failure ( New York Heart Academy ( NYHA ) functional class CHF IIIV ) unstable angina pectoris , myocardial infarction , percutaneous transluminal coronary angioplasty ( PTCA ) coronary artery bypass graft ( CABG ) surgery less three month prior inform consent stroke less six month prior inform consent sustain ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant arrhythmia determine investigator hypertrophic obstructive cardiomyopathy , hemodynamically relevant stenosis aortic mitral valve insulindependent diabetes mellitus whose diabetes stable control previous three month nightshift worker routinely sleep daytime whose working hour include midnight 4:00 AM know allergic hypersensitivity component formulation investigation concomitant therapy lithium , cholestyramine colestipol resin . noncompliance study medication ( define less 80 % 120 % ) runin period current treatment antihypertensive agent clinical condition , opinion investigator , would allow safe completion protocol safe administration telmisartan , amlodipine hydrochlorothiazide</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>